HCM
ALXN

Harvey Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Harvey Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,200
Closed -$220K – 89
2021
Q2 		$220K Buy
+1,200
New +$206K 0.07% 77
2021
Q1 		– Sell
-47,806
Closed -$7.47M – 83
2020
Q4 		$7.47M Sell
47,806
-6,305
-12% -$810K 3.03% 9
2020
Q3 		$6.19M Buy
54,111
+4,570
+9% +$493K 2.76% 9
2020
Q2 		$5.56M Sell
49,541
-8,100
-14% -$860K 2.75% 10
2020
Q1 		$5.17M Sell
57,641
-3,875
-6% -$380K 3.49% 11
2019
Q4 		$6.65M Buy
61,516
+27,806
+82% +$2.97M 2.95% 9
2019
Q3 		$3.3M Buy
+33,710
New +$3.8M 1.64% 24

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Harvey Capital Management's ALXN Position: Q3 2021 in Review

Harvey Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,200 shares — an estimated $220K sold.

Harvey Capital Management first reported a position in ALXN in Q3 2019 and held it in 7 quarters. The position peaked at $7.47M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Harvey Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Harvey Capital Management sold 1,200 Alexion Pharmaceuticals shares in Q3 2021, an estimated $220K.
  • Harvey Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 7 quarters.
  • Harvey Capital Management's Alexion Pharmaceuticals position peaked at $7.47M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Harvey Capital Management's 13F filing for Q3 2021, filed 25 Oct 2021.